Phase I Study of the HDAC Inhibitor Vorinostat With Chemotherapy and Radiation Therapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
This phase I trial will escalate doses of the histone deacetylase inhibitor (HDAC)
vorinostat to a chemoradiation platform for cisplatin, pemetrexed and radiation to a dose of
70Gy in NSCLC patients with unresectable IIIA and dry IIIB disease. The endpoint will be to
determine MTD of the combination.
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To assess that safety and maximally tolerated dose of vorinostat in combination with chemoradiation for unresectable locally advanced NSCLC.
toxicity assessments will occur weekly
Ranee Mehra, MD
Fox Chase Cancer Center
United States: Institutional Review Board
|Fox Chase Cancer Center||Philadelphia, Pennsylvania 19111|
|Medical University of South Carolina||Charleston, South Carolina 29425-0721|
|Moffitt Cancer Cetner||Tampa, Florida 33612|